Tobira Therapeutics Inc Stock Nasdaq

Stocks

20/10/16	Tobira Therapeutics : Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting	BU
03/10/16	Tobira Therapeutics : Announces Presentations Related to Cenicriviroc’s Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting	BU
21/09/16	TBRA Brower Piven Commences An Investigation Into The Proposed Sale Of Tobira Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	BU
21/09/16	Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Tobira Therapeutics, Inc. to Allergan plc for $28.35 Per Share Is Fair to Shareholders	BU
20/09/16	TOBIRA PHARMACEUTICALS, INC. Rigrodsky & Long, P.A. Announces Investigation Of Buyout	BU

24/10/16	TOBIRA fait gagner plus de 40 000 euros à un investisseur !
20/09/16	Allergan achète Tobira, spécialiste du traitement de la Nash

1 day

+6.05%

Manager	Title	Age	Since
Robert Michael CEO	Chief Executive Officer	55	-
Scott Reents DFI	Director of Finance/CFO	59	-
Jennifer M. Lagunas SEC	Corporate Secretary	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TOBIRA THERAPEUTICS INC	+6.05%	+12.17%	-	-	0
WUXI APPTEC CO., LTD.	+4.16%	-0.30%	+58.96%	+94.17%	71.53B
ARGENX SE	-0.19%	-1.01%	+38.55%	+83.85%	60.12B
LONZA GROUP AG	-1.51%	+2.20%	+10.66%	+35.15%	48.85B
IQVIA HOLDINGS INC.	-0.05%	+0.37%	+41.54%	+38.67%	44.28B
REVOLUTION MEDICINES, INC.	+0.38%	+7.61%	+339.53%	+684.33%	43.83B
BEONE MEDICINES AG	+0.18%	+0.26%	+7.41%	+105.01%	41.53B
CELLTRION, INC.	-0.67%	-0.45%	+4.47%	+46.37%	30.13B
WUXI BIOLOGICS (CAYMAN) INC.	+4.77%	+6.46%	+41.54%	+22.78%	27.98B
INSMED INCORPORATED	-1.29%	-3.55%	-20.74%	+349.90%	25.25B
Average	+1.23%	+0.48%	+57.99%	+162.25%	43.72B
Weighted average by Cap.	+0.85%	+0.63%	+63.17%	+153.57%

Employees

Sector